Alexis Weston

The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer

Raffaella Soldi, Tithi Ghosh, Alexis Weston et al. · PLoS ONE · 2020 · 82 citations · Full text

Life Sciences, Molecular Biology, Oncology +16

Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells

Sumati Gupta, Alexis Weston, Jared Bearrs et al. · Prostate Cancer and Prostatic Diseases · 2016 · 47 citations · Full text

Medicine, Oncology, Pharmacology +16

Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells

Sumati Gupta, Kelly Doyle, Timothy L. Mosbruger et al. · Oncotarget · 2018 · 27 citations · Full text

Medicine, Cancer Biology, Oncology +17

Histone Deacetylase Inhibition Has Targeted Clinical Benefit in <i>ARID1A</i> -Mutated Advanced Urothelial Carcinoma

Sumati Gupta, Daniel J. Albertson, Timothy J. Parnell et al. · Molecular Cancer Therapeutics · 2018 · 24 citations · Full text

Medicine, Oncology, Pharmacology +13

Abstract 3077: Preclinical studies of SR-8314, a highly selective ENPP1 inhibitor and an activator of STING pathway

Alexis Weston, Trason Thode, Rubén M. Muñoz et al. · Cancer Research · 2019 · 19 citations

Life Sciences, Immunology, Oncology +14